The appointment of a new CEO by Astellas Pharma—Japan’s fourth largest pharma company—is unlikely to slow down its development of gene therapies—efforts boosted by the recent lifting of a ...

Shares of Taysha Gene Therapies (NASDAQ ... involved in the gene therapy field, after the Astellas collaboration news I chose to reenter the stock ahead of 1H 23 Rett data updates.

Astellas has said it will book a $170 million ... both in early-stage clinical development – along with DMD gene therapies AT702, AT751 and AT753. The full financial impact of the delay to ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer ... universal donor cell and gene editing technology it obtained ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

Astellas Gene Therapies is turning out the lights at a California production plant. In a move expected to impact around 100 employees, Astellas Gene Therapies is closing its Eccles ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target ...

Astellas’s gene therapy division formed from the 2020 acquisition of Audentes Therapeutics, which brought a pipeline of gene therapies in various stages of development for rare inherited disorders.

In light of this, Astellas, a global pharmaceutical company based in Tokyo, Japan, has set a long-term goal of advancing cell and gene therapies for treating eye diseases. Degenerative eye ...

No identified affiliates for Astellas Gene Therapies in the 2024 election cycle. Contributions to 527s are not included in the Individuals, PACs, Soft (Indivs), or Soft (Orgs) columns, so the sum of ...